Lung Cancer

Lung Cancer
2023-07-10T00:00:00.000+01:00
Ongoing

Furmo-004

Furmo-004
Lung cancer

A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations

A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations

Trial overview

Clinical Area

Medical Oncology

Disease / Condition

Lung

Study Phase

III

Trial Identifiers

Registration number: NCT05607550

https://clinicaltrials.gov/study/NCT05607550

 

GenesisCare Location(s)
North Shore
location pin icon

North Shore Health Hub, Tower A, Level 1, 7 Westbourne St, St Leonards, NSW, 2065, Australia

phone icon (02) 8037 4100 email icon admin.northshore@genesiscare.com
NSW
North Shore
Principal Investigator(s)
Medical Oncologist

Prof. Nick Pavlakis

BSc MBBS MMed PhD FRACP

Prof. Nick Pavlakis
location pin icon

Frenchs Forest (Oncology) +1

View Profile
Profile Image - Prof. Nick Pavlakis

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.